全动脉移植在动脉血运重建试验中的效果
本研究为ART试验的探索性分析,按实际接受的移植物类型比较单动脉移植、多动脉移植和全动脉移植的远期结局。结果显示,与单动脉移植相比,多动脉移植和全动脉移植的10年死亡率呈显著下降趋势,全动脉移植的晚期死亡风险和复合终点风险均显著降低。
要点
- 与单动脉移植相比,全动脉移植与更低的晚期死亡风险相关(HR 0.68)。
- 全动脉移植还显著降低死亡/心梗/卒中及再次血运重建的复合风险(HR 0.71)。
- 多动脉移植和全动脉移植均可改善冠脉搭桥术后临床结局,全动脉移植可能带来额外获益。
核心结论
- 与单动脉移植相比,多动脉移植和全动脉移植均是改善冠脉搭桥术后临床结局的有价值策略,但全动脉移植可能提供进一步获益。
研究设计与样本
- 基于ART试验的探索性分析,采用按实际接受移植物(as-treated)原则,仅纳入接受至少3支移植物的患者。
- 最终人群包括单动脉移植组1084例、多动脉移植组(2支或以上动脉移植物加额外大隐静脉)1010例、全动脉移植组(仅3支或以上动脉移植物)390例。
- 采用逆概率治疗加权进行组间比较。
主要发现
- 与单动脉移植组相比,多动脉移植和全动脉移植组的10年死亡率呈显著下降趋势(趋势检验P = .02)。
- 全动脉移植组与最低的晚期死亡风险相关(风险比0.68;95%置信区间0.48-0.96;P = .03)。
- 全动脉移植组与死亡/心肌梗死/卒中及再次血运重建复合终点的显著风险降低相关(风险比0.71;95%置信区间0.53-0.94;P = .02)。
临床怎么用
- 在冠脉搭桥术中,可考虑优先使用多支动脉移植物以改善远期生存,全动脉移植可能带来额外获益。
局限性
- 本研究为ART试验的探索性分析,采用按实际接受移植物的as-treated原则,并非意向性治疗分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Arterial Revascularization Trial (ART) was designed to compare 10-year survival in bilateral versus single internal thoracic artery grafts. The intention-to-treat analysis has showed comparable outcomes between the 2 groups but an explanatory analysis suggested that those receiving 2 or more arterial grafts had better survival. Whether the exclusive use of arterial grafts provide further benefit is unclear. METHODS: We performed an exploratory analysis of the ART based on conduits actually received (as-treated principle). From ART cohort, only patients receiving at least 3 grafts were included. The final population consisted of 1084, 1010, and 390 patients in the single arterial graft (SAG) group, in the multiple arterial graft (MAG) group (2 or more arterial grafts with additional saphenous veins) and total arterial graft (TAG) group (3 or more arterial grafts only) respectively. Inverse probability of treatment weighting was used for comparison. RESULTS: When compared with the SAG group, there was a significant trend toward a reduction of 10-year mortality in the MAG and TAG group (test for trend P = .02). The TAG group was associated with the lowest risk of late mortality (hazard ratio, 0.68; 95% confidence interval, 0.48-0.96; P = .03) and with a significant risk reduction of the composite of death/myocardial infarction/stroke and repeat revascularization (hazard ratio, 0.71; 95% confidence interval, 0.53-0.94; P = .02). CONCLUSIONS: When compared with SAG, both MAG and TAG represent valuable strategies to improve clinical outcomes following coronary artery bypass grafting but TAG can potentially provide further benefit.
引用
- Taggart DP, Gaudino MF, Gerry S, et al. Effect of total arterial grafting in the Arterial Revascularization Trial. J Thorac Cardiovasc Surg. 2020. PMID: 32305186. doi:10.1016/j.jtcvs.2020.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。